Orum Therapeutics Outside Director Resignation Reduces Board Independence to 25%

Orum Therapeutics announced on June 18, 2026 that outside director Geoffrey Harris Meyerson voluntarily resigned due to personal reasons.
Following the resignation, the total number of registered directors decreased from 5 to 4, and the ratio of outside directors fell from 40% to 25%.
From a minority shareholder perspective, the weakened board independence may require closer monitoring of minority rights protection in future key decisions.
[AI Summary]This voluntary resignation has limited short-term stock price impact, but the reduced outside director ratio slightly increases governance risk. No equity changes or capital raising events are involved, so direct impact on enterprise value is minimal.